BCDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BCDA is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to invest. The stock is trading weakly, lacks supportive news or catalyst momentum, and the latest financials show ongoing losses with deteriorating margins. The only meaningful positive is strong insider buying, but that is not enough to outweigh the bearish technical setup and weak fundamentals. Given the user wants a direct answer and is unwilling to wait for an ideal entry, the clear decision is to avoid buying now.
The technical picture is bearish. MACD histogram is negative and expanding, showing downside momentum is still building. RSI_6 at 33.5 is near oversold but not a strong reversal signal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Price at 1.10 is hovering just above key support at 1.095, with the next support at 1.067 and resistance at 1.141-1.187. The pattern suggests weak price structure and limited upside momentum.
["Insiders are buying, with buying amount up 510.81% over the last month.", "Price is near short-term support around 1.095, which could allow a technical bounce."]
["No news in the recent week, so there is no event-driven catalyst.", "Bearish moving average structure and expanding negative MACD momentum.", "Latest quarter showed net loss of -1.984 million and EPS deterioration.", "Gross margin fell to 0, indicating no operating profitability improvement.", "No recent congress trading data and no identifiable politician/influential figure activity.", "Hedge funds are neutral, so institutional conviction is weak."]
In 2025/Q4, BioCardia reported revenue of 0, flat year over year, which indicates no sales growth. Net income was -1.984 million, worsening 13.59% YoY, and EPS fell to -0.19, down 62% YoY. Gross margin declined to 0, down 100% YoY. Overall, the latest quarter shows weak operating performance and no clear fundamental growth trend.
No analyst rating or price target data was provided, so there is no visible trend in Wall Street upgrades, downgrades, or target changes. Based on the available information, analysts' pros would likely center on insider buying and speculative rebound potential, while the cons would dominate: losses, no revenue growth, and a weak technical setup.
